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DFG—Research Center and Cluster of Excellence for Regenerative Therapies, TU-Dresden, Fetscherstrasse 105, 01307 Dresden, GermanyDown syndrome (DS) was ﬁrst described in 1866 by John Langdon the developing brain, they observed decreased nuclear levels of cyclin
Down and it is now recognized as themost common chromosomal dis-
order and cause of intellectual disability (Haydar and Reeves, 2012). De-
spite its prevalence (roughly 1 in 1000 births), the cause of the disease
was not identiﬁed until 1959 when karyotyping enabled the identiﬁca-
tion of trisomy 21 as responsible for the majority of DS cases (Haydar
and Reeves, 2012). The complete sequence of chromosome 21 was
determined in the year 2000 (Hattori et al., 2000). Yet, as researchers
have discovered time and again, knowledge of an organism's genetic
sequence does not necessarily translate into a precise understanding
of molecular and cellular processes. Almost sixty years have passed
since the cause of the disease was identiﬁed; yet the mechanisms un-
derlying DS remain obscure.
In this issue of EBioMedicine, Najas et al. expandour knowledge of DS
by showing that the dosage of the evolutionarily conserved tyrosine
kinase Dyrk1a, encoded by a gene located on chromosome 21 and trip-
licated in DS, alters the cell cycle, and hence the fate, of neural stem cells
(Najas et al., 2015-in this issue).
During mammalian corticogenesis, radial glial (RG) cells primarily
divide to either expand their own population or produce intermediate
progenitors (IPs). IPs have limited proliferative potential and pre-
dominantly generate neurons (Taverna et al., 2014). Interestingly,
both the regulation of the switch of RG cells from expansion to gen-
eration of IPs as well as the proliferative potential of IPs are intimate-
ly linked to cell cycle length (Borrell and Calegari, 2014). Speciﬁcally,
the G1 phase is known to lengthen as neurogenesis progresses and
overexpression of cell cycle regulators such as cyclin D1 shortens G1
and promotes proliferative (at the expense of neurogenic) divisions
(Borrell and Calegari, 2014).
Changes in cell cycle regulation and cell fate change of neural pro-
genitors were already reported in trisomic mouse models of DS
(Haydar and Reeves, 2012) and it was also known that Dyrk1a could
somehow inﬂuence both cell cycle progression and neurogenesis
in vitro and in vivo (Soppa et al., 2014; Yabut et al., 2010). However,
these previous studies could not assess the dose-dependent effect of
Dyrk1a and quantify its effects on speciﬁc phases of the cell cycle. To
address this, Najas and colleagues generated a number of mouse lines
in which either three or one allele of Dyrk1a was present. Focusing onDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.01.010.
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more in the single-allele, haploinsufﬁcient Dyrk1a line. Explaining this
phenotype, Dyrk1a was found to phosphorylate cyclin D1 in vitro and
likely disrupt its trafﬁcking and degradation. Consistent with a decrease
in the levels of cyclin D1, the authors found that an increase in the
Dyrk1a gene dosage caused a lengthening of both G1 and S phases.
This correlated with a transient increase in IPs followed by their prema-
ture depletion, which resulted in a transient increase in neurons at
mid-neurogenesis followed by an overall reduction in the total neuronal
output of the postnatal brain. Haploinsufﬁcient mice displayed a con-
verse phenotype, shedding light on the mechanistic link between
gene-dosage of Dyrk1a and developmental malformations associated
with DS.
To explain the parallel effect of Dyrk1a on the cell cycle and fate of
neural progenitors, the authors refer to previous reports showing that
lengthening G1 by decreasing the activity of cyclin D1 induces the pre-
mature generation of neurons and depletion of the stem cell pool
(Borrell and Calegari, 2014). This is indeed consistentwith observations
by Najas et al. atmid/late-corticogenesis. Yet it is puzzling that more IPs
and less neurons were also observed during early corticogenesis,
which is the opposite of what one would expect from amanipulation
that lengthens G1 (Borrell and Calegari, 2014). The authors propose
that this might be explained by intrinsic differences in progenitor
cells and/or environmental cues present at early versus late stages
of corticogenesis. Yet, this does not entirely solve the issue since re-
ports have shown that lengthening G1 results in a transient increase
in neurons both at the onset (Calegari and Huttner, 2003) as well as
at mid-neurogenesis (Lange et al., 2009). Perhaps, instead of differ-
ences in progenitors and/or cues within the niche, this discrepancy
might be explained by the fact that previous studies were performed
acutely and, often, tissue-speciﬁcally. While Najas et al. obtained an
exquisite control of gene dosage, their manipulations were neither
temporally nor spatially controlled among tissues physiologically
expressing Dyrk1a.
Nevertheless, the powerful animal models generated and character-
ized by Najas et al. will be extremely useful in future research. They
open up a number of possibilities, not only to study the pathology of
DS during development, but also to investigate the role of Dyrk1a in
the neurophysiology of postnatal neurons as these are known to display
reduced synaptic activity and abnormal gene expression (Haydar and
Reeves, 2012), highlighting the pleiotropic effects of this complex
disease.the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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